值得注意的是，东阳光药近日公告，集团持续深化AI战略布局，推出面向PROTAC机制的AI智能研发平 台，实现从数据底座到"干湿闭环"，数据规模与结构粒度均显着领先于现有公开数据库，为AI驱动的 PROTAC理性设计提供了全面、系统的数据基础，加速PROTAC先导化合物的理性设计与临床转化。 智通财经APP获悉，东阳光药(06887)午后涨超6%，截至发稿，涨6.55%，报46.2港元，成交额3062.89万 港元。 消息面上，1月16日，自主研发的1类创新药奥洛格列净胶囊已获国家药监局批准上市，用于单药或联合 二甲双胍改善成人2型糖尿病患者的血糖控制。东阳光药相关负责人表示，奥洛格列净的获批是东阳光 药在慢性病长期管理版图中迈出的扎实一步。 ...

Group 1 - The company Dongyangguang Pharmaceutical has received approval from the National Medical Products Administration of China for its SGLT-2 inhibitor, Ologliptin capsules, which are intended for improving blood glucose control in adults with type 2 diabetes [1] - The approval is based on two Phase III clinical trials that demonstrated statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with improvements in fasting blood glucose and postprandial blood glucose [1] - The product also showed additional metabolic benefits, including weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood glucose, weight, and blood pressure [1] Group 2 - Diabetes is now the third most serious chronic non-communicable disease globally, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The company has a comprehensive product line in diabetes treatment, including five insulin products that have been approved and are consistent in effectiveness, safety, and quality with original formulations [2] - The new product approval will enhance the company's diabetes product portfolio, and the company plans to leverage its established production system and marketing network for rapid commercialization while exploring further clinical applications for diabetes complications [2]

Group 1 - The company Dongyangguang Pharmaceutical has received approval from the National Medical Products Administration of China for its innovative drug, Ologliptin capsules, which are designed to improve blood sugar control in adults with type 2 diabetes [1] - The approval is based on two Phase III clinical trials that demonstrated statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with improvements in fasting blood glucose and postprandial blood glucose [1] - The product also offers additional metabolic benefits such as weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood sugar, weight, and blood pressure [1] Group 2 - Diabetes has become the third most serious chronic non-communicable disease globally, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The company has a comprehensive product line in the diabetes treatment field, including five insulin products that have been approved and are consistent in efficacy, safety, and quality with original formulations [2] - The approval of the new product will enhance the company's diabetes product portfolio, and it plans to leverage its established production system and marketing network for rapid commercialization while exploring further clinical applications for diabetes complications [2]

Group 1 - Dongyangguang Pharmaceutical (06887.HK) announced that its self-developed SGLT-2 inhibitor, Oloklignet capsules (brand name: Dongzean, specifications: 20mg, 50mg), received approval from the National Medical Products Administration of China for marketing, aimed at improving blood glucose control in adult patients with type 2 diabetes, either as monotherapy or in combination with metformin [1] - The registration approval was based on two multicenter, randomized, double-blind, placebo-controlled Phase III clinical studies, which showed statistically significant reductions in HbA1c levels after 24 weeks of treatment, along with significant improvements in fasting blood glucose and postprandial blood glucose [1] - The product also demonstrated additional metabolic benefits, including weight loss and blood pressure reduction, aligning with the current trend of comprehensive management of diabetes focusing on blood glucose, weight, and blood pressure [1] Group 2 - Diabetes has become the third most serious chronic non-communicable disease globally, following cancer and cardiovascular diseases, with the International Diabetes Federation reporting a diabetes prevalence rate of 13.79% among adults (ages 20-79) in China, translating to approximately 148 million patients, the highest in the world [2] - Over 90% of these cases are type 2 diabetes, with a poor medication adherence rate and an effective blood glucose control rate of only 50.1% [2] - The company has a comprehensive product line in the diabetes treatment field, having developed five insulin products that have been approved for marketing, all of which are consistent in efficacy, safety, and quality with original formulations and have been included in the national drug centralized procurement [2] - The approval of the new product will further enrich the company's diabetes product line, leveraging its established production system and marketing network for rapid commercialization, while also exploring clinical applications in diabetes complications to expand the range of indications [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 自願性公告 – 1 – 目前，糖尿病已成為全球範圍內繼腫瘤、心腦血管病之後，第三位嚴重危害人類 健康的慢性非傳染性疾病。國際糖尿病聯盟(IDF)第11版《糖尿病地圖》數據顯示， 中 國 成 人（ 20 – 79 歲 ）糖 尿 病 患 病 率 達 13.79 % ， 患 者 數 量 達 1.48 億 ， 位 居 全 球 首 位 。 其 中 2 型 糖 尿 病 佔 比 超 90 % ， 患 者 臨 床 用 藥 依 從 性 普 遍 不 佳 ， 血 糖 有 效 控 制 率僅有50.1 %。 本集團長期深耕糖尿病治療領域，擁有全面的產品規劃，佈局了完整的產品線。 本集團 ...

Major Events - Longi Technology (09611) plans to globally offer 52.2591 million H-shares from January 14 to January 19 [1] - CK Life Sciences (00013) announced the results of the SACHI III study published in The Lancet [1] - Dongyang Sunshine Pharmaceutical (06887) launched an AI-driven R&D platform targeting the PROTAC mechanism, continuing to deepen its AI strategic layout [1] - Dongyao Pharmaceutical-B (01875) received a cash offer from WuXi AppTec (02268) at a premium of approximately 99%, with resumption of trading on January 15 [1] - Valiant Pharmaceuticals-B (09887) received Fast Track designation from the US FDA for its bispecific antibody, Opalizumab (LBL-024) [1] - Xunqi (03317) entered into a strategic cooperation framework agreement with Jinyong Investment to support digital transformation in investment research, trading, and risk management [1] Operating Performance - CITIC Securities (06030) reported a net profit attributable to shareholders of 30.051 billion yuan for 2025, an increase of 38.46% year-on-year [1] - CITIC Bank (00998) reported a net profit attributable to shareholders of 70.618 billion yuan for 2025, a year-on-year increase of 2.98% [1] - China General Nuclear Power New Energy (01811) completed a cumulative power generation of 19,000 GWh in 2025, a decrease of 0.8% year-on-year [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 106.21 billion yuan for 2025 [1] - WuXi AppTec (02268) issued a profit warning, expecting a net profit growth of over 38% year-on-year for 2025 [1] - Jinyu Group (02009) issued a profit warning, anticipating a net loss attributable to shareholders of 900 million to 1.2 billion yuan for 2025 [1] - Saijing Technology (00580) issued a profit alert, expecting a net profit increase of approximately 30.0% for 2025 [1] - Beijing Beichen Industrial Co., Ltd. (00588) issued a profit warning, expecting a net loss attributable to shareholders of 2.696 billion to 3.38 billion yuan for 2025 [1]

Group 1 - The core viewpoint of the articles highlights the significant advancements in AI-driven drug development, particularly through the launch of the PROTAC mechanism AI research platform by Dongyangguang Pharmaceutical, which aims to accelerate the rational design and clinical translation of lead compounds, addressing the "undruggable" dilemma [1][2] - The AI pharmaceutical sector is entering a phase of clinical validation, shifting market focus from technological concepts to practical implementation and industrialization pathways, as evidenced by partnerships like NVIDIA's collaboration with Eli Lilly, which involves a $1 billion investment over five years [1] - Dongyangguang Pharmaceutical has developed four core models for molecular screening, generation, PBPK, and retro-synthetic analysis, and has introduced AI-driven models such as HEC-PharmAI, which includes a knowledge base of over 210,000 formulation recipes and thousands of literature and patents [1] Group 2 - The benefits of AI in drug development are evident, as demonstrated by Dongyangguang Pharmaceutical's THRβ agonist project for metabolic fatty liver, where AI pre-screening reduced the number of animal experiments from 100 to about 10, cutting development time by 50% [2] - AI technology can shorten research and development cycles by nearly 40%, save at least 10% in costs, and increase success rates to approximately 14% [2] - Major pharmaceutical companies are adopting a "dual-track" strategy for AI application, focusing on immediate effects while also investing in foundational assets, such as Dongyangguang Pharmaceutical's establishment of an AI research institute and acquisition of related AI assets [2]

Core Viewpoint - Dongyangguang Pharmaceutical is advancing its AI strategy by launching an AI-driven research and development platform focused on the PROTAC mechanism, aiming to provide a comprehensive data foundation for rational design and clinical translation of PROTAC lead compounds [1][2]. Group 1: AI Strategy and Platform Development - The company is building a high-quality, structured PROTAC-specific database (HEC PROTAC DB) that integrates molecular structures, degradation activity, physicochemical properties, and pharmacokinetic parameters from clinical pipelines, patents, and literature [2]. - The database currently includes over 30,000 PROTAC molecules, more than 500 POI ligands, over 1,000 types of linkers, 200 E3 ligands, and more than 150 targets, significantly surpassing existing public databases in data scale and structural granularity [2]. - An AI molecular generation and screening platform has been developed based on this database, creating a "data-generation-computational validation-experimental feedback" closed loop to accelerate the rational design and clinical translation of PROTAC lead compounds [2]. Group 2: Collaboration and Drug Development - The company is enhancing its AI drug development strategy through collaborations with industry leaders such as Beijing Deep Technology Co., Ltd. and Huawei Cloud Computing Technology Co., Ltd., establishing six proprietary models covering the entire drug discovery process [3]. - The first AI-driven small molecule drug, HEC169584, targeting metabolic-associated fatty liver disease (MASH), has entered clinical phase I, showing high in vitro activity against THR-β cells and strong liver targeting, with reduced impact on the thyroid axis and heart [3].

Core Insights - The company is advancing its AI strategy by launching an AI-driven research platform focused on PROTAC mechanisms, which enhances the rational design of lead compounds and clinical translation through a comprehensive data foundation [1][2] Group 1: AI Strategy and Platform Development - The AI platform aims to create a high-quality, structured PROTAC-specific database (HEC-PROTACDB) that integrates molecular structures, degradation activities, physicochemical properties, and pharmacokinetic parameters from clinical pipelines, patents, and literature [2] - The database currently includes over 30,000 PROTAC molecules, more than 500 POI ligands, over 1,000 types of linkers, 200 E3 ligands, and more than 150 targets, significantly surpassing existing public databases in data scale and structural granularity [2] Group 2: Drug Development and Collaborations - The company is enhancing its AI drug development strategy through collaborations with industry leaders such as Beijing DeepTech and Huawei Cloud, establishing six proprietary models that cover the entire drug discovery process from molecular design to prescription design [3] - The first AI-driven small molecule drug, HEC169584, targeting metabolic-associated fatty liver disease (MASH), has entered clinical phase I, showing high in vitro activity against THR-β cells and strong liver targeting, with reduced impact on the thyroid axis and heart [3]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 – 1 – SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 自願性公告 推出全球領先的PROTAC機制AI智能研發平台 本 公 告 由 廣 東 東 陽 光 藥 業 股 份 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團」）自願刊發。 本集團持續深化AI戰略佈局，推出面向PROTAC機制的AI智能研發平台，實現從 數據底座到「乾濕閉環」，數據規模與結構粒度均顯著領先於現有公開數據庫，為 AI 驅 動的 PROTAC 理 性設 計 提供 了 全面 、 系 統的 數 據基 礎 ，加 速 PROTAC 先導 化 合物的理性設計與臨床轉化。 研發背景：破解「不可成藥」困局，PR ...